DISCERN™, a highly accurate, minimally invasive test to diagnose Alzheimer’s Disease
Lori La Bey talks with Frank Amato, CEO and President, SYNAPS Dx, which offers DISCERN™, the first highly accurate, minimally invasive test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. DISCERN is commercialized under the Clinical Laboratory Improvement Amendments (CLIA) and is reimbursed by Medicare.
Learn:
Listen and Subscribe to Alzheimer’s Speaks on Apple Podcast
https://podcasts.apple.com/us/podcast/alzheimers-speaks/id986940432
Listen and Subscribe to Alzheimer’s Speaks on Spotify
https://open.spotify.com/show/255okRnEgfCUqXq1NWcrT3
Contact SYNAPS Dx
Website https://www.synapsdx.com/
Website https://discerntest.com/
Frank LinkedIn www.linkedin.com/in/frank-amato-3b2a162/
SYNAPS Dx LinkedIn www.linkedin.com/company/synapsdx/
SYNAPS Dx Facebook www.facebook.com/discerntest
SYNAPS Dx Twitter (X) @getdiscern
SYNAPS Dx Instagram @getdiscern
Contact Lori La Bey with questions or branding needs at https://www.alzheimersspeaks.com/
Alzheimer's Speaks Radio - Shifting dementia care from crisis to comfort around the world one episode at a time by raising all voices and delivering sound news, not just sound bites since 2011.
Alzheimer's Speaks is part of the Senior Resource Podcast Network.
Support this Show: https://alzheimersspeaks.com/donate-now/
See omnystudio.com/listener for privacy information.
Create your
podcast in
minutes
It is Free